New drug duo tested in fight against tough cancers
NCT ID NCT05111561
Summary
This early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes. The main goal is to see what side effects occur and find a dose that is safe for future testing. Researchers will also look for early signs that the treatment can shrink or stop the growth of these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
Conditions
Explore the condition pages connected to this study.